

BiRd (clarithromycin, lenalidomide, dexamethasone): An update on long term lenalidomide therapy in previously untreated patients with multiple myeloma

Adriana Rossi¹, Tomer Mark¹, David Jayabalan^{1,2}, Paul Christos³, Faiza Zafar¹, Karen Pekle¹, Roger Pearse¹, Selina Chen-Kiang², Morton Coleman¹, and Ruben Niesvizky¹

¹Division of Hematology and Medical Oncology, Department of Medicine, Myeloma Center, Weill Cornell Medical College, New York Presbyterian Hospital, NY, USA; ² Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, NY, USA; ³ Division of Biostatistics and Epidemiology, Department of Public Health, Weill Cornell Medical College, NY, USA.

Table S1 – Patient Characteristics

Characteristic	N = 72
Median age, years (range)	63 (36-83)
Sex, n (%)	
Male	41 (57)
Female	31 (43)
ISS classification, n (%)	
Stage I	33 (46)
Stage II	26 (36)
Stage III	13 (18)
Immunoglobulins, heavy-chain type, n (%)	
IgA	16 (22)
IgG	44 (61)
Bence Jones protein	12 (17)
Prior Malignancies	
Breast cancer	3
Prostate cancer	3
Melanoma	2
Lymphoma	1
Skin SCC	1
Skin BCC	1

Figure S1. Patient Disposition

